 |
|
|
| |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Interim Analysis Shows Increase in EVR
|
| |
| |
44th EASL April 23-26 2009 Copenhagen
Reported by Jules Levin
B.R. Bacon,1 M.L. Shiffman,2 J.K. Lim,3 A. Berman,4 V.K. Rustgi,5 E.B. Keeffe,6,7 and STEALTH C-3 Investigators
1St. Louis University Medical Center, St. Louis, MO, USA 2Virginia Commonwealth University Medical Center, Richmond, VA, USA 3Yale University Medical
Center, New Haven, CT, USA 4Florida Center for Gastroenterology, Largo, FL, USA, 5Georgetown University Medical Center, Washington, DC, USA and
6Romark Institute for Medical Research, Tampa, FL, USA and 7Stanford University Medical Center, Stanford, CA, USA
|
| |
|
|
|
|
|
